TCIM
MRTX

TIAA CREF Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

TIAA CREF Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$15.4M Sell
210,115
-60,791
-22% -$4.14M 0.01% 824
2018
Q4 		$11.5M Buy
270,906
+215,077
+385% +$8.57M 0.01% 888
2018
Q3 		$2.63M Sell
55,829
-605
-1% -$33.7K ﹤0.01% 1977
2018
Q2 		$2.78M Buy
+56,434
New +$2.13M ﹤0.01% 1994
2017
Q2 		– Sell
-51,202
Closed -$266K – 3193
2017
Q1 		$266K Sell
51,202
-8,839
-15% -$48.4K ﹤0.01% 2948
2016
Q4 		$285K Sell
60,041
-19,106
-24% -$104K ﹤0.01% 2986
2016
Q3 		$523 Buy
79,147
+28,775
+57% +$153K ﹤0.01% 2829
2016
Q2 		$275K Buy
50,372
+14,977
+42% +$239K ﹤0.01% 3049
2016
Q1 		$757K Hold
35,395
– – ﹤0.01% 2617
2015
Q4 		$1.12M Buy
35,395
+2,666
+8% +$94.2K ﹤0.01% 2512
2015
Q3 		$1.13M Sell
32,729
-903
-3% -$27.3K ﹤0.01% 2503
2015
Q2 		$1.06M Buy
33,632
+6,323
+23% +$186K ﹤0.01% 2669
2015
Q1 		$801K Hold
27,309
– – ﹤0.01% 2737
2014
Q4 		$506K Sell
27,309
-321
-1% -$5.41K ﹤0.01% 2959
2014
Q3 		$484K Hold
27,630
– – ﹤0.01% 2979
2014
Q2 		$553K Buy
+27,630
New +$533K ﹤0.01% 2989

Other funds holding MRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TIAA CREF Investment Management's MRTX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 22% in Q1 2019, selling an estimated $4.14M and leaving 210,115 shares worth $15.4M. The position accounts for 0.01% of the portfolio, ranked #824.

TIAA CREF Investment Management first reported a position in MRTX in Q2 2014 and has held it in 16 quarters since. 159 funds tracked by Wall St. Rank hold MRTX as of Q1 2019.

  • TIAA CREF Investment Management held 210,115 shares of Mirati Therapeutics, Inc. Common Stock worth $15.4M as of Q1 2019.
  • TIAA CREF Investment Management sold 60,791 Mirati Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $4.14M.
  • Mirati Therapeutics, Inc. Common Stock made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #824 holding.
  • TIAA CREF Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and has held it in 16 quarters since.
  • 159 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.